Insights on the CD40 Ligand Market to 2022 | Industry Statistics, Emerging Demands, Forecast to 2028

The global CD40 Ligand market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). CD154, also known as CD40 ligand or CD40L, is a member of the TNF superfamily of molecules that is largely expressed on activated T cells. It attaches to CD40 (protein) on antigen-presenting cells (APC), resulting in a variety of consequences depending on the kind of target cell.CD40 expression has also been found in non-hematopoietic cells, including bladder cancer cells, where the CD40 antigen was first discovered, as well as , breast, nasopharyngeal, liver, and cervical carcinoma cells.

To Request a Sample of our Report on CD40 Ligand Market: https://www.omrglobal.com/request-sample/cd40-ligand-market

Ovarian cancer is the most common type of cancer which has higher response rates as compared to those women who only received a checkpoint inhibitor. It causes the abnormality of certain cells in the . Such cancers can arise in the epithelial cells that cover the ovarian surface. However, a significant improvement has been observed in the therapies for the treatment of cancer, it is still one of the major causes of mortalities globally. As per the American Cancer Society in 2016, around 22,000 women in the US received a new diagnosis of ovarian cancer, and around 14,000 women succumbed to this disease. The oncolytic virus therapy serves as a promising approach for the treatment of cancer. Bladder cancer is the tenth most common cancer across the globe. In 2018, there were 17 million new cases of bladder cancer across the globe. As per Cancer Research UK, the incidence of cancer is estimated to reach 62% during 2018-2040 across the globe. Bladder cancer is considered the fourth most common cancer in men whereas it is the least common cancer in women. Further, there is an increasing incidence of bladder cancer in emerging countries such as China and India attributed to increasing smoking and tobacco consumption. In India, bladder cancer is considered the 18th most common cancer in 2018. As per the National Institute of cancer prevention and research (NICPR), there were 18,296 new cases of bladder cancer in India in 2018. Further, there were 10,231 mortalities that were recorded in 2018.

Market Coverage

· The market number available for - 2021-2028

· Base year- 2021

· Forecast period- 2022-2028

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Targovax ASA, and Bristol-Myers Squibb Company, among others.

(Get 15% Discount on Buying this Report)

A full Report of CD40 Ligand Market is Available @ https://www.omrglobal.com/industry-reports/cd40-ligand-market

Global CD40 Ligand Market Report by Segment

By Type

· ISF-35

· LOAd700

· MEDI-4920

· MegaCD40L

· Others

By Application

· Hepatitis B

· Bladder Cancer

· Liver Cancer

· Others

Global CD40 Ligand Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.